1. Home
  2. MOB vs RNTX Comparison

MOB vs RNTX Comparison

Compare MOB & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MOB
  • RNTX
  • Stock Information
  • Founded
  • MOB 2008
  • RNTX 2001
  • Country
  • MOB Israel
  • RNTX United States
  • Employees
  • MOB N/A
  • RNTX N/A
  • Industry
  • MOB Real Estate Investment Trusts
  • RNTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • MOB Real Estate
  • RNTX Health Care
  • Exchange
  • MOB Nasdaq
  • RNTX Nasdaq
  • Market Cap
  • MOB 24.1M
  • RNTX 26.5M
  • IPO Year
  • MOB 2022
  • RNTX N/A
  • Fundamental
  • Price
  • MOB $6.50
  • RNTX $1.36
  • Analyst Decision
  • MOB Strong Buy
  • RNTX Hold
  • Analyst Count
  • MOB 1
  • RNTX 1
  • Target Price
  • MOB $10.00
  • RNTX N/A
  • AVG Volume (30 Days)
  • MOB 542.4K
  • RNTX 114.6K
  • Earning Date
  • MOB 08-12-2025
  • RNTX 08-14-2025
  • Dividend Yield
  • MOB N/A
  • RNTX N/A
  • EPS Growth
  • MOB N/A
  • RNTX N/A
  • EPS
  • MOB N/A
  • RNTX N/A
  • Revenue
  • MOB $2,826,361.00
  • RNTX N/A
  • Revenue This Year
  • MOB N/A
  • RNTX N/A
  • Revenue Next Year
  • MOB N/A
  • RNTX N/A
  • P/E Ratio
  • MOB N/A
  • RNTX N/A
  • Revenue Growth
  • MOB N/A
  • RNTX N/A
  • 52 Week Low
  • MOB $0.85
  • RNTX $1.04
  • 52 Week High
  • MOB $6.60
  • RNTX $4.40
  • Technical
  • Relative Strength Index (RSI)
  • MOB 69.59
  • RNTX 55.67
  • Support Level
  • MOB $5.30
  • RNTX $1.06
  • Resistance Level
  • MOB $6.60
  • RNTX $1.48
  • Average True Range (ATR)
  • MOB 0.70
  • RNTX 0.13
  • MACD
  • MOB 0.09
  • RNTX 0.03
  • Stochastic Oscillator
  • MOB 90.10
  • RNTX 71.09

About MOB Mobilicom Limited

Mobilicom Ltd is a provider of cybersecurity and smart solutions for drones, robotics & autonomous platforms. As a high-tech company, it designs, develops, and delivers smart solutions targeting global drone, robotics, and autonomous system manufacturers. Its products include OS3 Platform Software, ICE Cybersecurity Software, MCU Mesh Networking, SkyHopper Datalinks, Mobile Ground Control Stations and System Engineering Services.

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: